A Phase II(a) clinical trial has shown that a new vitamin D receptor agonist can be used alongside docetaxel and prednisone to reduce prostate specific antigen (PSA) levels in patients with prostate cancer. The study was presented at the 22nd EORTC-NCI-AACR (European Organisation for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research) Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

Full article